Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
about
Targeted therapies and immunotherapy in non-small-cell lung cancerNew targeted treatments for non-small-cell lung cancer - role of nivolumabNot all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategyThe steady progress of targeted therapies, promising advances for lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCImplications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung CancerThe influence of subclonal resistance mutations on targeted cancer therapyThe Evolution of Therapies in Non-Small Cell Lung CancerIn vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerNew developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Implementing Genome-Driven Oncology.Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerOsimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapyEstablishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung CancerClinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors.Genetic Evidence for XPC-KRAS Interactions During Lung Cancer DevelopmentAfatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR InhibitorsAfatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data.New data on clinical decisions in NSCLC patients with uncommon EGFR mutations.Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.Kinase inhibitor-responsive genotypes in EGFR mutated lung adenocarcinomas: moving past common point mutations or indels into uncommon kinase domain duplications and rearrangements.Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations.XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancerClinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.Resisting Resistance: Targeted Therapies in Lung Cancer.Metastatic lung cancer in the age of targeted therapy: improving long-term survival.Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions.Targeting Chromatin-Mediated Transcriptional Control of Gene Expression in Non-Small Cell Lung Cancer Therapy: Preclinical Rationale and Clinical Results.Safety and efficacy of targeted agents monotherapy in advanced NSCLC.Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress.Afatinib in the first-line treatment of epidermal-growth-factor-receptor mutation-positive non-small cell lung cancer: a review of the clinical evidence.Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer.Safety of gefitinib in non-small cell lung cancer treatment.Response to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma with the Rare Epidermal Growth Factor Receptor Mutation S768I: a Retrospective Analysis and Literature Review.The safety of afatinib for the treatment of non-small cell lung cancer.
P2860
Q26738986-739FF8F2-76EF-4562-A20E-E485F101FCF5Q26740988-C92C3806-08BE-4604-B91F-21A122E86763Q26744284-EB18E110-3805-4C7C-BE95-71DAFE10742DQ26746895-0D85EA5C-74EB-426C-9AF7-9731E77E0514Q26747276-2A9A2513-0818-4B74-819A-1C67B480B2D7Q26764917-36CEAE08-5458-488B-9EFA-EF742555DE52Q26781693-BBA99544-C46B-424F-91AD-49BCEE9AA12BQ26786932-5ED698F2-E54C-494B-A863-892FC5CC1135Q27853236-CE10486E-0578-4F00-9795-DE6155A25454Q28075511-2066D574-91D1-4B45-BD69-7F16C6FA1F8DQ30235979-A1F4F558-E929-4161-BC1B-03AE153C0F26Q33740707-B94C59AB-92F8-4267-87EF-2D1679B4C8EFQ33757134-D282B593-87F9-43AB-894C-2D83C2C59316Q33776876-6C74254D-C60F-4608-B331-EAA3579ABD7FQ33779181-D0879DA4-5BD5-4F0A-9CC7-FE83D7D9FEB8Q33897441-051A9025-4704-49B1-AEAE-2F8FDA070A0CQ34501246-1ED3017F-EF1F-47FD-B846-7CDFBD50D821Q36116376-31A740D5-DD9D-4F22-804F-AE9F68FCFA23Q36132436-467AE6C4-FE25-44B1-8976-7496028BE37AQ36215079-DE8EE154-E35D-4150-8FE2-D1D84CF333AEQ36351290-A01C0F3B-1E21-43A7-8738-78250A173959Q37060709-50F93F95-33B7-4B88-9434-9AECC7F3B49AQ37094986-835372DA-5EF5-4E3E-B4E5-9B2B699F6FF6Q37138970-ADF9FE23-4DEA-4760-8605-57FFBCE441C7Q37273873-8F280116-DDDC-4FC5-95F9-74C6680CC51FQ37388238-6E07D36A-E156-4A34-9651-3E2885299202Q37584403-6713B5C6-648D-48CB-85B2-4A95669570C3Q37687088-05FBF53D-E53C-4E26-A56F-75F955F6D46FQ37697306-EE8B2B7B-B064-4A08-B09E-1A08D4CD4226Q37698613-110F87DB-3A01-4E9B-A47C-9BB6EEBCBD01Q37702099-F1B1CD71-5C4B-4406-9755-AB6E995CE0ABQ38582589-C2D511B0-E50E-4583-B58D-804506BFFD9FQ38630725-01A7AE71-554C-4FCC-927A-5BA04D3BCD1BQ38646686-DD08A0B7-4529-4F1C-B07F-CD6A4B970D33Q38756061-F7B58280-FB78-4EB6-BEC8-46771C6A44ECQ38767492-09D2B175-80D5-4A5D-AE63-997FE6AEC9EFQ38790929-32ED2222-B475-461F-AA38-46F62221E1D5Q38841473-8AC5FF93-D341-4675-874A-D7EA9B39C36CQ38931077-22973106-6D88-42E3-A0E5-08AFF492E2A7Q38955468-8510D18C-8ED8-444E-9219-BBDD38773741
P2860
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Clinical activity of afatinib ...... 2, LUX-Lung 3, and LUX-Lung 6.
@en
type
label
Clinical activity of afatinib ...... 2, LUX-Lung 3, and LUX-Lung 6.
@en
prefLabel
Clinical activity of afatinib ...... 2, LUX-Lung 3, and LUX-Lung 6.
@en
P2093
P50
P1433
P1476
Clinical activity of afatinib ...... 2, LUX-Lung 3, and LUX-Lung 6.
@en
P2093
Chun-Ming Tsai
Daniel Massey
Lecia V Sequist
Martin Schuler
Nobuyuki Yamamoto
Sai-Hong I Ou
Sarayut Lucien Geater
Victoria Zazulina
Yi-Long Wu
P304
P356
10.1016/S1470-2045(15)00026-1
P577
2015-06-04T00:00:00Z